Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Physical examination, Platelet count, Thrombocytopenic purpura
Clinical narrative: Immune thrombocytopenia; This literature-non-study case was reported in a literature article and describes the occurrence of THROMBOCYTOPENIC PURPURA (Immune thrombocytopenia) in a 58-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.   No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced THROMBOCYTOPENIC PURPURA (Immune thrombocytopenia) (seriousness criterion medically significant). The patient was treated with ROMIPLOSTIM for Immune thrombocytopenia, at an unspecified dose and frequency and FOSTAMATINIB for Immune thrombocytopenia, at an unspecified dose and frequency. At the time of the report, THROMBOCYTOPENIC PURPURA (Immune thrombocytopenia) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Physical examination: abnormal notable for diffuse petechiae along the arms, legs, and abdomen along with numerous oral lesions and gingival bleeding.. On an unknown date, Platelet count: 3 x 10^9/l platelet count of 3 x10^9/L with all other cell lines within normal limits, abnormal Given IVIG multiple times but platelet count remained refractory and improved Improved.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered THROMBOCYTOPENIC PURPURA (Immune thrombocytopenia) to be related.    Concomitant medications were not reported.  Patient presented with acute onset of mucosal bleeding, petechiae and easy bruising.  Patient was treated with first line therapy of platelet transfusion, high dose steroids and intravenous immunoglobulin (IVIG) multiple times but platelet count remained refractory.  Company Comment: This is a literature case that concerns a 58-year-old male patient with no medical history reported, who experienced the unexpected serious AESI event of Thrombocytopenic purpura which occurred 3 weeks after receiving the first dose of mRNA-1273 Vaccine. Patient went to hospital after acute onset of mucosal bleeding, petechiae and easy bruising. On Physical examination abnormal diffuse petechiae were noted along the arms, legs, and abdomen along with numerous oral lesions and gingival bleeding. He was noted to have a platelet count of 3 x109/L with all other cell lines within normal limits. A diagnosis of idiopathic thrombocytopenic purpura was made. Patient was treated with first-line therapy of platelet transfusion, high dose steroids, and intravenous immunoglobulin (IVIG) and romiplostim (a thrombopoietin receptor agonist)-and fostamatinib (an inhibitor of spleen tyrosine kinase). The platelet count improved and his symptoms were resolved. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.; Sender's Comments: This is a literature case that concerns a 58-year-old male patient with no medical history reported, who experienced the unexpected serious AESI event of Thrombocytopenic purpura which occurred 3 weeks after receiving the first dose of mRNA-1273 Vaccine. Patient went to hospital after acute onset of mucosal bleeding, petechiae and easy bruising. On Physical examination abnormal diffuse petechiae were noted along the arms, legs, and abdomen along with numerous oral lesions and gingival bleeding. He was noted to have a platelet count of 3 x109/L with all other cell lines within normal limits. A diagnosis of idiopathic thrombocytopenic purpura was made. Patient was treated with first-line therapy of platelet transfusion, high dose steroids, and intravenous immunoglobulin (IVIG) and romiplostim (a thrombopoietin receptor agonist)-and fostamatinib (an inhibitor of spleen tyrosine kinase). The platelet count improved and his symptoms were resolved. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.